More about

Cabozantinib

News
May 22, 2020
5 min read
Save

Immunotherapy or TKI: Debating the best HCC treatment options

Immunotherapy or TKI: Debating the best HCC treatment options

Thomas A. Abrams, MD, senior physician at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, spoke with Healio about treatment options for patients with hepatocellular carcinoma. He discusses first-line treatment, guidance on aspirin use and important, recent FDA approvals.

View more